Low molecular weight heparin protection against oxalate-induced oxidative renal insult

Clinica Chimica Acta; International Journal of Clinical Chemistry
Arjunan Rajeswari, P Varalakshmi

Abstract

Oxidative stress has emerged as an invariable feature of calculogenesis, the process of stone formation. The cytoprotective action of low molecular weight heparin (LMWH) in calcium oxalate-induced oxidative renal injury in experimental calculogenesis was studied. A renal membrane injury model involving gentamicin (40 mg/kg body weight) and 2% ammonium oxalate was used. Rats induced with gentamicin and ammonium oxalate were investigated for any impairment of cellular redox status as revealed by renal superoxide dismutase, catalase, glutathione peroxidase, xanthine oxidase activities and glutathione, ascorbate levels. In renal membrane protein activities such as aminotransferases in kidney and lactate dehydrogenase, total protein in urine of rats rendered lithogenic were assessed and compared with healthy vehicle-treated controls. The biochemical index of tissue lipid peroxidation was assessed in terms of malondialdehyde formation. LMWH was co-administered (250 microg/kg body weight) to gentamicin- and ammonium oxalate-dosed rats. The extent of oxidative damage was indicated by the increased lipid peroxidation in the renal tissues of gentamicin- and ammonium oxalate-administered groups. The decline in the antioxidative status of ...Continue Reading

References

May 21, 1986·Biochimica Et Biophysica Acta·T P Devasagayam
Feb 4, 1974·Biochemical and Biophysical Research Communications·J HögbergS Orrenius
Jun 1, 1972·Analytical Biochemistry·A K Sinha
Feb 9, 1973·Science·J T RotruckW G Hoekstra
Feb 1, 1996·Kidney International·C ScheidM Menon
Sep 1, 1999·Kidney International·Y Ishikawa, M Kitamura
Jan 12, 2000·Current Opinion in Nephrology and Hypertension·G Remuzzi
Nov 30, 2000·Journal of the American Society of Nephrology : JASN·Monica CeolErwin D Schleicher
Nov 28, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Dimitrios S GoumenosJohn G Vlachojannis
Jul 4, 2003·Critical Reviews in Eukaryotic Gene Expression·Julie A JonassenCheryl R Scheid
Jul 25, 2003·European Journal of Pharmacology·José Pedraza-ChaverríRogelio Hernández-Pando
Oct 25, 2003·European Journal of Pharmacology·Perinkulam Ravi Deepa, Palaninathan Varalakshmi
Jan 28, 2004·Journal of Endourology·Marklyn Jones, Manoj Monga

❮ Previous
Next ❯

Citations

Jun 14, 2008·Expert Opinion on Investigational Drugs·Leo R Zacharski, Agnes Yy Lee
Dec 9, 2008·European Journal of Pharmacology·José García-de-la-AsunciónElena Domenech
Nov 16, 2007·European Journal of Pharmacology·Coothan Kandaswamy VeenaPalaninathan Varalakshmi
Mar 3, 2007·The Journal of Pharmacy and Pharmacology·Coothan Kandaswamy VeenaPalaninathan Varalakshmi
Jun 8, 2017·BioMed Research International·Nianlin XieXiaofei Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.